Improved i.p. drug delivery with bioadhesive nanoparticles

Area of Science:

• Oncology
• Nanomedicine
• Drug Delivery

Background:

• Intraperitoneal (i.p.) chemotherapy using biodegradable nanoparticles shows promise for treating peritoneal carcinomatosis in ovarian and uterine serous carcinomas.
• The effectiveness of current nanoparticle chemotherapy is limited by rapid lymphatic clearance from the peritoneal cavity.
• Developing strategies to prolong nanoparticle retention is crucial for enhancing therapeutic outcomes.

Purpose of the Study:

• To develop and evaluate a unique formulation of bioadhesive nanoparticles (BNPs) for improved peritoneal retention of chemotherapeutic agents.
• To assess the therapeutic efficacy and toxicity profile of BNPs loaded with epothilone B (EB) in preclinical models of chemotherapy-resistant uterine serous carcinoma.

Main Methods:

• Formulation of bioadhesive nanoparticles (BNPs) designed to interact with peritoneal mesothelial cells.
• Loading of the potent chemotherapeutic agent epothilone B (EB) into BNPs.
• Evaluation of nanoparticle retention in the peritoneal space.
• Assessment of therapeutic efficacy and systemic toxicity in xenograft models of uterine serous carcinoma resistant to i.p. chemotherapy.

Main Results:

• The developed BNPs demonstrated significant interaction with mesothelial cells, leading to extended retention within the peritoneal cavity.
• BNPs loaded with epothilone B (EB) exhibited significantly reduced systemic toxicity compared to free EB.
• BNPs loaded with EB showed superior therapeutic efficacy against i.p. chemotherapy-resistant uterine serous carcinoma xenografts compared to non-BNPs and free EB.

Conclusions:

• Bioadhesive nanoparticles represent a promising strategy to overcome the challenge of rapid lymphatic clearance in peritoneal chemotherapy.
• BNPs loaded with epothilone B offer a potentially safer and more effective treatment for peritoneal carcinomatosis, particularly in chemotherapy-resistant cases.
• This approach holds potential for improving treatment outcomes in patients with ovarian and uterine serous carcinomas presenting with peritoneal spread.